A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors.

Trial Profile

A Broad Multi-Histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-Small Cell Lung, Head and Neck, Hepatocellular and Renal Cell Carcinomas and Pheochromocytoma and Thyroid Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2012

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Pheochromocytoma; Renal cancer; Solid tumours; Thyroid cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Actual patient number is 37 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top